Fosun Pharma (600196.SH) released its first three quarters results, with net profit attributable to shareholders of RMB 2.667 billion, up 5.71% year on year.

Zhitong Finance APP News, Fosun Pharma (600196.SH) disclosed its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of RMB 30.463 billion, up 3.64% year on year; net profit attributable to shareholders of the listed company was RMB 2.667 billion, up 5.71% year on year; net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 1.706 billion, up 8.42% year on year; basic earnings per share were RMB 1.01.